AnaptysBio Inc (ANAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Summary

AnaptysBio Inc (AnaptysBio) is a biotechnology company that develops antibody drug candidates. The companys product pipeline comprises ANB020 and ANB019. Its ANB020 is a product candidate used for the treatment of severe adult asthma and severe adult peanut allergy and ANB019 is a product candidate used for the treatment of rare inflammatory diseases such as generalized pustular psoriasis and palmoplantar pustular psoriasis. AnaptysBio utilizes its SHM-XEL platform to identify and mature antibodies with desired functional activity. It uses somatic hypermutation platform for antibody discovery and optimizatiom. The company works in collaboration with other organizations. AnaptysBi is headquartered in San Diego, California, the US.

AnaptysBio Inc (ANAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

2
List of Tables 3
List of Figures 4
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
AnaptysBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
AnaptysBio Inc, Medical Devices Deals, 2011 to YTD 2017 9
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
AnaptysBio Raises USD40 Million in Series D Financing 11
AnaptysBio Raises US$2 Million In Venture Financing 12
AnaptysBio Secures US$8 Million In Series C Financing 12
Partnerships 13
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 13
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 14
AnaptysBio Enters Into Co-Development Agreement With Novartis 14
AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 15
Celgene Enters into Co-Development Agreement with AnaptysBio 16
AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 17
Licensing Agreements 18
Tesaro Enters Into Licensing Agreement With AnaptysBio For Multiple Immuno-Oncology Programs 18
Equity Offering 19
AnaptysBio Raises USD86.3 Million in IPO 19
Asset Transactions 20
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 20
AnaptysBio Inc - Key Competitors 22
Key Employees 23
Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
May 11, 2017: AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update 25
Mar 08, 2017: AnaptysBio Announces 2016 Operating Results and Pipeline Progress 26
Corporate Communications 28
Jan 11, 2017: AnaptysBio Announces The Appointment Of Dominic Piscitelli As Chief Financial Officer 28
Apr 18, 2016: AnaptysBio Appoints Dr. Matthew Moyle As Chief Scientific Officer 29
Product News 30
Sep 26, 2016: AnaptysBio Announces Checkpoint Receptor Agonist Antibody Portfolio 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List Of Tables


AnaptysBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
AnaptysBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
AnaptysBio Inc, Deals By Therapy Area, 2011 to YTD 2017 8
AnaptysBio Inc, Medical Devices Deals, 2011 to YTD 2017 9
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
AnaptysBio Raises USD40 Million in Series D Financing 11
AnaptysBio Raises US$2 Million In Venture Financing 12
AnaptysBio Secures US$8 Million In Series C Financing 12
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 13
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 14
AnaptysBio Enters Into Co-Development Agreement With Novartis 14
AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 15
Celgene Enters into Co-Development Agreement with AnaptysBio 16
AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 17
Tesaro Enters Into Licensing Agreement With AnaptysBio For Multiple Immuno-Oncology Programs 18
AnaptysBio Raises USD86.3 Million in IPO 19
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 20
AnaptysBio Inc, Key Competitors 22
AnaptysBio Inc, Key Employees 23
AnaptysBio Inc, Subsidiaries 24

List Of Figures


AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
AnaptysBio Inc, Medical Devices Deals, 2011 to YTD 2017 9

AnaptysBio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

AnaptysBio Inc (AnaptysBio) is a biotechnology company that develops antibody drug candidates for therapeutic areas such as inflammation and immuno-oncology. The companys product pipeline includes ANB020 and ANB019. Its ANB020,

USD 250 View Report

AnaptysBio Inc (ANAB) - Financial and Strategic SWOT Analysis Review

AnaptysBio Inc (ANAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring

USD 125 View Report

AnaptysBio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

AnaptysBio Inc (AnaptysBio) is a biotechnology company that develops antibody drug candidates for therapeutic areas such as inflammation and immuno-oncology. The companys product pipeline includes ANB020 and ANB019. Its ANB020,

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available